LAMEA Real World Evidence Solutions Market Size to 2022-2028

LAMEA Real World Evidence Solutions Market Size, Share & Industry Trends Analysis Report By Component, By Therapeutic Area, By End-user (Healthcare Companies, Healthcare Payers, Healthcare Providers), By Application, By Country and Growth Forecast, 2022 - 2028

Published Date: February-2023 | Number of Pages: 111 | Format: PDF | Report ID: KBV-13656

Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support


Get in-depth analysis of the COVID-19 impact on the LAMEA Real World Evidence Solutions Market

Market Report Description

The Latin America, Middle East and Africa Real World Evidence Solutions Market would witness market growth of 10.7% CAGR during the forecast period (2022-2028).

RWE is being utilized by pharma in more novel ways. RWE is used by some for clinical trial planning and recruiting. In contrast, others use it for post-market safety and unfavorable event monitoring or financial analyses relating to payer reimbursement. Some companies are incorporating ways to continuous learning into their lifecycle of product development.

Additionally, digital health innovation has considerably improved wearable technology's capabilities, which has led to a rise in the usage of recent technological advancements in clinical studies. More than 1,000 completed or continuing clinical research involving wearables were listed in the database, mainly in oncology, neuroscience, and respiratory and metabolic illnesses. These developments are fostering the market for real-world evidence solutions.

The regional healthcare industry's future is shaped by several elements, which is why the trend is altering. Rising healthcare costs, shifting population & disease demographics, increased healthcare quality emphasis, medical data digitization, rising demand for regional clinical & economic data, and a general influence of worldwide trends in the medical industry are some of the other factors. However, for the region to fully benefit from RWE in treatment decisions, it must overcome some obstacles, such as accepting the worth that RWE puts to healthcare decisions, and fostering trust among stakeholders. Additionally, establishment of the validity & reliability of the databases utilized to generate RWE, investment in the generation of local data, and improving technical capabilities would benefit the market. These factors would further proliferate the undertaking of high-quality RWE research while protecting patient confidentiality. These rising healthcare sector would drive the demand of Real World Evidence Solutions Market in LAMEA.

The Brazil market dominated the LAMEA Real World Evidence Solutions Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $933 million by 2028.The Argentina market is exhibiting a CAGR of 11.3% during (2022 - 2028). Additionally, The UAE market would display a CAGR of 10.4% during (2022 - 2028).

Based on Component, the market is segmented into Services and Data Set. Based on Therapeutic Area, the market is segmented into Oncology, Cardiology, Neurology, Diabetes, Respiratory and Others. Based on End-user, the market is segmented into Healthcare Companies, Healthcare Payers, Healthcare Providers and Others. Based on Application, the market is segmented into Drug Development & Approvals, Medical Device Development & Approvals, Reimbursement/Coverage & Regulatory Decision Making and Post Market Safety & Adverse Events Monitoring. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

Free Valuable Insights: The Global Real World Evidence Solutions Market is Predict to reach $65.1 Billion by 2028, at a CAGR of 8%

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include IBM Corporation, Oracle Corporation, Medpace Holdings, Inc., IQVIA Holdings, Inc., ICON plc, PerkinElmer, Inc., Parexel International Corporation (Phoenix Parentco, Inc.), PPD, Inc. (Thermo Fisher Scientific, Inc.), UnitedHealth Group, Inc. (Optum, Inc.), and Syneos Health, Inc.

Scope of the Study

Market Segments Covered in the Report:

By Component

  • Services
  • Data Set

By Therapeutic Area

  • Oncology
  • Cardiology
  • Neurology
  • Diabetes
  • Respiratory
  • Others

By End-user

  • Healthcare Companies
  • Healthcare Payers
  • Healthcare Providers
  • Others

By Application

  • Drug Development & Approvals
  • Medical Device Development & Approvals
  • Reimbursement/Coverage & Regulatory Decision Making
  • Post Market Safety & Adverse Events Monitoring

By Country

  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

  • IBM Corporation
  • Oracle Corporation
  • Medpace Holdings, Inc.
  • IQVIA Holdings, Inc.
  • ICON plc
  • PerkinElmer, Inc.
  • Parexel International Corporation (Phoenix Parentco, Inc.)
  • PPD, Inc. (Thermo Fisher Scientific, Inc.)
  • UnitedHealth Group, Inc. (Optum, Inc.)
  • Syneos Health, Inc.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Related Reports:

Global Real World Evidence Solutions Market Report 2022-2028

North America Real World Evidence Solutions Market Report 2022-2028

Asia Pacific Real World Evidence Solutions Market Report 2022-2028

Europe Real World Evidence Solutions Market Report 2022-2028

Purchase Report


Special Pricing & Discounts

  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities